Development Strength
At the heart of Pfizer is an uncommon commitment and aptitude for bringing new innovations to market. By combining our global regulatory and clinical development experience with your discovery, together we can deliver on the promise of your technology.
Pfizer:
- Employs approximately 13,000 scientists worldwide—with experts in virtually every scientific and business discipline.
- Currently has 114 new medicines in Phase 1 through Phase 3 development—more than any other company—targeting a wide range of important therapeutic areas.
- Has delivered on some of the industry's most successful development strategies—leading to record sales for products like LIPITOR® (atorvastatin calcium) and the rapid expansion of LYRICA® (pregabalin).
Put our worldwide regulatory expertise to work for your products.
In 2007 alone, Pfizer completed more than 9,000 submissions to regulators. These submissions detailed a vast array of pivotal, outcomes, post-marketing, and follow-on studies, supporting clinical development strategies that are aligned with today's global regulatory, third-party payer, and commercial environments.
Pfizer maximized the potential of LIPITOR by identifying new indications (e.g., non-fatal heart attacks, fatal and non-fatal strokes), and patient populations (diabetes patients at risk of heart disease), and designing and implementing clinical programs to demonstrate LIPITOR's utility in each of these areas. In addition, Pfizer built novel relationships with payers to keep LIPITOR accessible and demonstrated, through clinical and real-world data, that it can help patients avoid more costly and invasive disease interventions. These development strategies help make LIPITOR the largest selling drug in the world.
View LIPITOR U.S. Physician Prescribing Information
The LYRICA fibromyalgia program is an example of how quickly and effectively Pfizer can execute pivotal studies to support additional indications and grow commercial value. Even though the new studies involved more than 3,000 patients, it took just 2 years from the start of the first Phase 3 study to regulatory submission. As a result, Pfizer was first-to-market in the U.S. with a product for fibromyalgia. Building on this success, we plan to submit a fibromyalgia regulatory filing in Europe, and have designed a follow-on clinical program to broaden the neuropathic and post-operative pain indication in the U.S.
View LYRICA U.S. Physician Prescribing Information
"Pfizer is committed to flexible, transparent and mutually beneficial long-term relationships with its partners. By joining forces, we can bring quality therapies to patients worldwide. Let's work together for a healthier world."
—Bill Ringo, Senior Vice President,
Worldwide Business Development
Strategy & Innovation
- Contact Us
- Investors
- Sitemap
- Careers
- Business to Business
- Terms of Use
- Global Network
- Privacy Policy
Copyright © 2002–2009 Pfizer Inc. All rights reserved. This information is intended only for residents of the United States. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. Pfizer Inc is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.
